The Increased Neuromedin B Is Associated with Poor Prognosis in Glioblastoma Multiforme

2021 ◽  
Author(s):  
Suqin Li ◽  
Qingjie Li ◽  
Fei Liu ◽  
Shihuan Li ◽  
Wenli Liao ◽  
...  
Keyword(s):  
Glioblastoma Multiforme ◽  
Poor Prognosis ◽  
Neuromedin B

Recent Advances on Glioblastoma Multiforme and Nano-drug Carriers: A Review

2019 ◽  
Vol 26 (31) ◽  
pp. 5862-5874 ◽  
Author(s):  
Wang Liao ◽  
Shengnuo Fan ◽  
Yuqiu Zheng ◽  
Shaowei Liao ◽  
Ying Xiong ◽  
...  
Keyword(s):  
Stem Cells ◽  
Glioblastoma Multiforme ◽  
Self Assembly ◽  
Poor Prognosis ◽  
Drug Delivery Systems ◽  
Drug Carriers ◽  
Therapeutic Resistance ◽  
Average Survival ◽  
Nano Drug Delivery ◽  
New Development

Glioblastoma Multiforme (GBM) is the most frequent glioma with a poor prognosis. The mainstay treatment for GBM is chemotherapy, but the average survival of GBM remains unsatisfactory due to therapeutic resistance. Poor permeability restricted by the Blood Brain Barrier (BBB) and the presence of Glioblastoma Stem Cells (GSCs) remain as two problems for chemotherapy. Recently, nanocarriers have attracted much attention in the research of GBM, owing to their advantages in self-assembly, biosafety, release controllability, and BBB penetrability, making them promising candidates for GBM treatment. This article aims to review the biologic signatures of BBB and GSCs, as well as the new development of nano-drug delivery systems to facilitate our understanding of targeted treatment for GBM.

Glioblastoma: Prognostic Factors and Predictive Response to Radio and Chemotherapy

2020 ◽  
Vol 27 (17) ◽  
pp. 2814-2825
Author(s):  
Francesco Fiorica ◽  
Maria Colella ◽  
Rosaria Taibi ◽  
Andrea Bonetti ◽  
Jacopo Giuliani ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Glioblastoma Multiforme ◽  
Poor Prognosis ◽  
Therapeutic Strategy ◽  
Biological Factors ◽  
Near Future ◽  
Predictive Response

: Glioblastoma multiforme (GBM) is characterized by poor prognosis despite an aggressive therapeutic strategy. In recent years, many advances have been achieved in the field of glioblastoma biology. : Here we try to summarize the main clinical and biological factors impacting clinical prognostication and therapy of GBM patients. From that standpoint, hopefully, in the near future, personalized therapies will be available.

scholarly journals Suprabasin—A Review

Genes ◽  
2021 ◽  
Vol 12 (1) ◽  
pp. 108
Author(s):  
Miroslav Pribyl ◽  
Zdenek Hodny ◽  
Iva Kubikova
Keyword(s):  
Glioblastoma Multiforme ◽  
Poor Prognosis ◽  
Current Knowledge ◽  
Original Description ◽  
Oesophageal Carcinoma ◽  
Secreted Proteins ◽  
Cornified Envelope ◽  
Physiological Conditions ◽  
Signalling Molecules ◽  
Human Genes

Among the ~22,000 human genes, very few remain that have unknown functions. One such example is suprabasin (SBSN). Originally described as a component of the cornified envelope, the function of stratified epithelia-expressed SBSN is unknown. Both the lack of knowledge about the gene role under physiological conditions and the emerging link of SBSN to various human diseases, including cancer, attract research interest. The association of SBSN expression with poor prognosis of patients suffering from oesophageal carcinoma, glioblastoma multiforme, and myelodysplastic syndromes suggests that SBSN may play a role in human tumourigenesis. Three SBSN isoforms code for the secreted proteins with putative function as signalling molecules, yet with poorly described effects. In this first review about SBSN, we summarised the current knowledge accumulated since its original description, and we discuss the potential mechanisms and roles of SBSN in both physiology and pathology.

scholarly journals Overexpression of c-Met is Associated with Poor Prognosis in Glioblastoma Multiforme: A Systematic Review and Meta-Analyses

2021 ◽  
Vol 22 (10) ◽  
pp. 3075-3080
Author(s):  
Jellyca Anton ◽  
Sudibio Sudibio ◽  
Handoko Handoko ◽  
Tiara Permata ◽  
Henry Kodrat ◽  
...  
Keyword(s):  
Systematic Review ◽  
Glioblastoma Multiforme ◽  
Poor Prognosis ◽  
Meta Analyses

Overexpression of GBP1 predicts poor prognosis and promotes tumor growth in human glioblastoma multiforme

2019 ◽  
Vol 25 (3) ◽  
pp. 275-290 ◽  
Author(s):  
Xiaoyan Ji ◽  
Hanting Zhu ◽  
Xiaoxiao Dai ◽  
Yujun Xi ◽  
Yujing Sheng ◽  
...  
Keyword(s):  
Glioblastoma Multiforme ◽  
Tumor Growth ◽  
Poor Prognosis ◽  
Human Glioblastoma ◽  
Human Glioblastoma Multiforme

Cost-Effective Analysis of Hypofractionated Versus Standard 30-Fraction IMRT in Patients With Poor Prognosis Glioblastoma Multiforme

2014 ◽  
Vol 90 (1) ◽  
pp. S589
Author(s):  
J.C. Ye ◽  
M. Yondorf ◽  
S.C. Pannullo ◽  
J.A. Boockvar ◽  
P.E. Stieg ◽  
...  
Keyword(s):  
Glioblastoma Multiforme ◽  
Poor Prognosis ◽  
Cost Effective ◽  
Effective Analysis ◽  
Patients With Poor Prognosis

scholarly journals Cytosine methylation of mature microRNAs inhibits their functions and is associated with poor prognosis in glioblastoma multiforme

2020 ◽  
Vol 19 (1) ◽  
Author(s):  
Mathilde Cheray ◽  
Amandine Etcheverry ◽  
Camille Jacques ◽  
Romain Pacaud ◽  
Gwenola Bougras-Cartron ◽  
...  
Keyword(s):  
Glioblastoma Multiforme ◽  
Poor Prognosis ◽  
Cytosine Methylation ◽  
Mature Micrornas

scholarly journals Leptomeningeal Disease in Glioblastoma: Endgame or Opportunity?

2021 ◽  
Author(s):  
Sarfraz Akmal ◽  
Elizabeth E. Ginalis ◽  
Nitesh V. Patel ◽  
Robert Aiken ◽  
Simon J. Hanft
Keyword(s):  
Systematic Review ◽  
Overall Survival ◽  
Glioblastoma Multiforme ◽  
Poor Prognosis ◽  
Standard Of Care ◽  
Intrathecal Chemotherapy ◽  
Therapeutic Strategies ◽  
Leptomeningeal Disease ◽  
Aggressive Cancer ◽  
Case Basis

Abstract Introduction: Glioblastoma is an aggressive cancer with a notoriously poor prognosis. Recent advances in treatment have increased overall survival, though this may be accompanied by an increased incidence of leptomeningeal disease (LMD). LMD carries a particularly severe prognosis and remains a late stage manifestation of glioblastoma without satisfactory treatment. The objective of this review is to survey the literature on treatment of LMD in glioblastoma and to more fully characterize the current therapeutic strategies. Methods: The authors performed a systematic review following PRISMA criteria on PubMed. Articles that included adult patients with LMD from glioblastoma multiforme were retrieved and reviewed. Results: LMD in glioblastoma patients is increasing in incidence, with reports of up to 21%. The overall survival without treatment is alarmingly brief, with patients surviving between 1.6-3.8 months. All studies showed that treatment does improve overall survival significantly, increasing to 11.7 months in one study. However, no one adjuvant or surgical therapy has been shown to improve survival in LMD significantly over another. Direct treatment methods include chemotherapy (standard, anti-angiogenic, intrathecal, immunotherapy), and radiation. Hydrocephalus is a complication in LMD that can be treated with ventriculoperitoneal shunt placement, however treating hydrocephalus and delivering intrathecal chemotherapy is a challenge. Conclusion: Though evidence remains lacking and there is no consensus, treatments show a trend towards improving survival and should be considered on a case-by-case basis. Further studies are necessary in the pursuit of a standard of care.

Sign in / Sign up

Export Citation Format

Share Document